The lawsuit claims Doximity executives repeatedly characterized their Newsfeed as the firm's primary revenue driver, citing record engagement and active prescriber metrics. Plaintiffs allege these assertions concealed the reality that the company was losing ground to competitors offering more aggressive pricing. Furthermore, the complaint asserts that Doximity falsely downplayed its reliance on banner ads and email newsletters, despite claims of maintaining a non-intrusive environment for physicians.
Doximity Faces Class Action Lawsuit Over Alleged Misleading Growth Claims
Investors who purchased Doximity, Inc. common stock between August 8, 2024, and May 13, 2026, are being urged to contact Robbins LLP regarding a pending class action lawsuit. The complaint alleges that the digital medical platform misled shareholders by overstating the revenue impact of its Newsfeed product while masking internal market share losses.
Financial disclosures throughout the class period triggered significant volatility in the company's valuation. On November 6, 2025, shares dropped 13% following an admission of slowing sales growth. Subsequent reports in February 2026 and May 2026 led to further declines of 17% and 23%, respectively, as the firm missed revenue guidance and analysts raised concerns about heightened market competition. Investors wishing to participate in the litigation as a lead plaintiff must file their requests by November 16, 2026. Robbins LLP is representing the class on a contingency fee basis.
Comments (0)
No comments yet. Be the first!